Macular Telangiectasia (MacTel): Causes, Risk Factors & Symptoms

Macular telangiectasia type 2 (MacTel) is a rare, bilateral neurodegenerative eye disease affecting the macula—the central part of the retina responsible for sharp, detailed vision. It involves abnormal widening and leakage of tiny blood vessels (telangiectasia) in the deep capillary plexus, often with secondary neurodegeneration.

Causes

The exact cause is not fully understood, but research suggests a combination of genetic predisposition, autoimmune dysregulation, and environmental factors contribute to its development. It is increasingly viewed as a primary neurodegenerative disorder with secondary vascular changes.

Risk Factors

• Age: Primarily affects adults over 50.
• Gender: Women are more likely to develop MacTel than men.
• Family History: Genetic predisposition increases risk; several loci identified.
• Cardiovascular Conditions: Hypertension and other vascular issues may elevate risk.
• Smoking: Identified as a potential risk factor for development and progression.

Symptoms

• Blurred or distorted central vision, especially for fine details and reading.
• Difficulty recognizing faces or distinguishing objects up close.
• Reduced color perception (faded or muted colors).
• Central dark spots or shadows in the visual field (scotomas).
• Sensitivity to bright lights (photophobia).

Diagnosis

An ophthalmologist diagnoses MacTel through a comprehensive eye exam including:

• Visual acuity testing.
• Dilated eye exam (may show subtle retinal graying, crystals, or telangiectasia).
• Fundus photography (retinal imaging).
• Optical coherence tomography (OCT) for cross-sectional macular images (shows cavitation, outer retinal loss).
• Fluorescein angiography to visualize retinal blood vessels and detect late leakage (often hypofluorescent early).
• OCT angiography (OCTA) for non-invasive visualization of deep capillary plexus abnormalities.

Treatment

There is currently no cure. Treatment focuses on slowing progression and managing symptoms:

• Anti-VEGF Injections: Medications like ranibizumab (Lucentis) and aflibercept (Eylea) reduce vessel leakage and retinal swelling in some patients.
• Laser Therapy: Photodynamic therapy (PDT) or micropulse laser may seal leaking vessels, but use is limited due to risk of further damage.
• Low Vision Aids: Magnifiers, telescopic lenses, and electronic magnifiers assist with daily tasks.
• Regular Monitoring: Ongoing follow-ups with a retina specialist are essential.
• Emerging Therapies: Neuroprotective agents and metabolic modulators are under investigation.

Outlook

Prognosis varies. Some experience slow progression over decades; others may have more rapid vision decline. Early detection and management help preserve central vision for many years.